Johnson & Johnson’s most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $133.00 short call and a strike $138.00 long call offers a potential 22.25% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $133.00 by expiration. The full premium credit of $0.91 would be kept by the premium seller. The risk of $4.09 would be incurred if the stock rose above the $138.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 35.27 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Trump’s FBI pick to face questions about independence
Wed, 12 Jul 2017 07:36:21 +0000
WASHINGTON (AP) — President Donald Trump’s pick to lead the FBI faces a confirmation hearing Wednesday that will undoubtedly focus on the political tumult surrounding his nomination, with both Democrats and Republicans seeking assurances of his independence from the White House.
These Small Biotechs Are Leading The Pack Today — Here’s Why
Tue, 11 Jul 2017 20:57:01 +0000
Arena and Amicus stocks led the biotech pack Tuesday on strong Phase 2 drug data and a favorable regulatory decision, respectively.
Johnson & Johnson earnings: A challenging second quarter poised for a turnaround
Tue, 11 Jul 2017 20:36:53 +0000
Johnson & Johnson’s first-quarter sales miss amid a challenging drug market disappointed investors. Don’t expect the company’s second-quarter earnings — scheduled before the open on July 18 — to be any …
Here’s Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today
Tue, 11 Jul 2017 19:47:07 +0000
On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.
3 Dividend Stocks That Laugh at Market Crashes
Tue, 11 Jul 2017 19:30:00 +0000
Smart investors know that including defensive stocks such as Costco, Johnson & Johnson, and McDonald’s in their portfolios can make a lot of sense.
Follow Us on Facebook